Global Leading Market Research Publisher QYResearch announces the release of its latest report “Dipsacus Extract – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Dipsacus Extract market, including market size, share, demand, industry development status, and forecasts for the next few years.
For consumers seeking natural alternatives for bone and joint health, conventional treatments for osteoporosis, osteoarthritis, and fractures rely on calcium supplements, NSAIDs, or prescription drugs (bisphosphonates) with side effects (gastrointestinal, renal). The Dipsacus extract addresses this through traditional Chinese medicine (TCM) bone health support: derived from the dried roots of Dipsacus asper (Xu Duan), this extract contains alkaloids, volatile oils, and triterpenoid saponins with pharmacological effects including liver and kidney tonification, tendon and bone strengthening, fracture healing promotion, and pregnancy maintenance. According to QYResearch’s updated model, the global market for Dipsacus Extract was estimated to be worth US$ 19.47 million in 2025 and is projected to reach US$ 33.55 million, growing at a CAGR of 8.2% from 2026 to 2032. In 2024, global production of Dipsacus Extract reached approximately 150 tons, with an average selling price of approximately US$ 130 per kilogram. Dipsacus Extract, extracted from the dried roots of the traditional Chinese medicine Dipsacus root, primarily contains alkaloids, volatile oils, and triterpenoid saponins. It has various pharmacological effects, including tonifying the liver and kidneys, strengthening tendons and bones, healing fractures, and maintaining pregnancy. It is used to treat low back and knee weakness, rheumatic pain, injuries from falls, and osteoporosis.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6098092/dipsacus-extract
1. Technical Architecture: Extraction Methods and Active Compounds
Dipsacus extract is segmented by physical form and extraction method, determining application and bioavailability:
| Form | Extraction Method | Key Active Compounds | Typical Purity | Price per kg (USD) | Market Share (2025) |
|---|---|---|---|---|---|
| Liquid | Solvent extraction (ethanol/water) | Triterpenoid saponins (dipsacus saponin A, B, C), alkaloids | 10-20% total saponins | $80-120 | 40% |
| Powder | Spray drying of liquid extract | Triterpenoid saponins, volatile oils, iridoid glycosides | 20-50% total saponins | $100-150 | 60% |
Key bioactive compounds and their pharmacological effects:
| Compound Class | Examples | Pharmacological Activity | Clinical Evidence |
|---|---|---|---|
| Triterpenoid saponins | Dipsacus saponin A, B, C | Osteoblast differentiation, bone formation | Moderate (animal studies, limited human) |
| Iridoid glycosides | Sweroside, loganic acid | Anti-inflammatory, analgesic | Moderate |
| Alkaloids | Dipsacaine, dipsacine | Muscle relaxation, pain relief | Limited |
| Phenolic acids | Chlorogenic acid, caffeic acid | Antioxidant, anti-inflammatory | Strong (general, not Dipsacus-specific) |
Key technical challenge – standardization of active compounds: Over the past six months, several advancements have emerged:
- Shaanxi Yongyuan Biotechnology (February 2026) introduced a standardized Dipsacus extract (30% total saponins, HPLC-verified) with batch-to-batch consistency (CV <5%), enabling reproducible clinical research and supplement manufacturing.
- Xian Tianxingjian Natural Bio-products (March 2026) commercialized a “water-soluble” Dipsacus powder (micronized, instantized) for beverage applications (functional drinks, smoothies), expanding beyond capsules and tablets.
- Ciyuan Biology (January 2026) launched a Dipsacus extract with enhanced bioavailability (liposomal encapsulation), increasing absorption by 3x (rat study), targeting premium nutraceutical market.
Industry insight – TCM bone health market context:
| Condition | Prevalence | Conventional Treatment | Dipsacus Extract Role |
|---|---|---|---|
| Osteoporosis | 200M+ women globally | Bisphosphonates (alendronate), calcium, vitamin D | Adjunct for bone density maintenance |
| Osteoarthritis | 500M+ globally | NSAIDs (ibuprofen, naproxen), acetaminophen | Anti-inflammatory, pain relief |
| Fracture healing | 15M+ annually (US) | Immobilization, surgery (internal fixation) | Accelerates callus formation |
| Low back pain | 500M+ episodes annually | NSAIDs, muscle relaxants, physical therapy | TCM pattern differentiation (kidney deficiency) |
2. Market Segmentation: Form and Application
The Dipsacus Extract market is segmented as below:
Key Players: Shaanxi Yongyuan Biotechnology (China), Shaanxi New Horizon Biotechnology (China), Xian Tianxingjian Natural Bio-products (China), Ciyuan Biology (China), Shaanxi Runze Xinqi Biotechnology (China), Shaanxi Sinuote Biotechnology (China)
Segment by Form:
- Powder – Largest segment (60% of 2025 revenue). Capsules, tablets, functional foods.
- Liquid – 40% of revenue. Tinctures, liquid extracts, functional beverages.
Segment by Application:
- Pharmaceutical – Largest segment (40% of revenue). TCM patent medicines, hospital preparations.
- Nutraceuticals – 35% of revenue (fastest-growing, 10% CAGR). Dietary supplements for bone and joint health.
- Cosmetics – 15% of revenue. Anti-aging creams, hair growth products.
- Food – 5% of revenue. Functional beverages, health foods.
- Others – Veterinary, research (5% of revenue).
Typical user case – osteoporosis supplement formulation: A nutraceutical company develops a bone health supplement combining Dipsacus extract (150mg) with calcium (500mg), vitamin D3 (800 IU), and vitamin K2 (100mcg). Target demographic: postmenopausal women (50+). Clinical claim: “supports bone mineral density and reduces fracture risk.” Annual production: 10 million capsules (1 capsule/day). Dipsacus extract cost: $0.03 per capsule ($0.03 × 365 = $11/year). Retail price: $30-40 per bottle (30-day supply). Gross margin: 70%.
Exclusive observation – “TCM modernization” trend: Dipsacus extract is a traditional Chinese medicine (TCM) herb used for centuries. Modern nutraceutical applications require standardization, safety data, and clinical evidence. Chinese manufacturers (Shaanxi Yongyuan, Shaanxi New Horizon, Tianxingjian, Ciyuan, Runze Xinqi, Sinuote) are investing in HPLC standardization (active compounds) and GMP-certified production, enabling export to Western markets (US, EU, Japan). TCM herbal extract exports from China grew 12% CAGR (2020-2025).
3. Regional Dynamics and Aging Population
| Region | Market Share (2025) | Key Drivers |
|---|---|---|
| Asia-Pacific | 65% | Largest production (China), domestic TCM market (China, Japan, Korea), aging population, fast-growing (9% CAGR) |
| North America | 20% | Growing nutraceutical demand (bone health, joint health), TCM acceptance |
| Europe | 10% | Herbal supplement market (Germany, UK, France), regulatory framework (Traditional Herbal Registration) |
| RoW | 5% | Emerging markets (Latin America, Middle East) |
Exclusive observation – “osteoporosis awareness” as growth driver: Aging global population (65+ projected 1.5B by 2050) increases osteoporosis and fracture risk. Dipsacus extract is positioned as a “natural” alternative to bisphosphonates (which have side effects: jaw osteonecrosis, atypical femur fractures). Dipsacus extract also targets “kidney deficiency” pattern in TCM (associated with aging-related bone loss), appealing to Asian consumers familiar with TCM concepts.
4. Competitive Landscape and Outlook
| Tier | Supplier | Key Strengths | Focus |
|---|---|---|---|
| 1 | Shaanxi Yongyuan Biotechnology (China) | Largest producer, GMP-certified, standardization (30% saponins), export focus | Pharmaceutical, nutraceutical |
| 1 | Shaanxi New Horizon Biotechnology (China) | Broad product portfolio, R&D (bioavailability enhancement) | Nutraceutical, cosmetics |
| 2 | Regional specialists | Tianxingjian, Ciyuan, Runze Xinqi, Sinuote (China) | Cost leadership, domestic market, niche applications |
Technology roadmap (2027-2030):
- Clinical trials for osteoporosis – Human RCTs (randomized controlled trials) to support EFSA/USDA structure/function claims. Pilot studies underway.
- Dipsacus + collagen combinations – Synergistic formulations targeting skin elasticity + bone health. Emerging segment.
- Sustainable cultivation – Wild Dipsacus is over-harvested; cultivated Dipsacus (farmed) with quality control (GACP – Good Agricultural and Collection Practices) is expanding.
With 8.2% CAGR and 150 tons produced in 2024, the Dipsacus extract market benefits from aging population, osteoporosis awareness, and TCM modernization. Key growth drivers: natural bone health demand, TCM globalization, and standardization (quality control). Risks include limited clinical evidence (mostly animal studies), competition from other bone health herbs (horsetail, nettle, red clover), and regulatory barriers (novel food approval in EU, DSHEA compliance in US).
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
